-
1
-
-
4644261592
-
Mechanisms of bone metastasis
-
Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004; 350(16):1655-1664.
-
(2004)
N Engl J Med
, vol.350
, Issue.16
, pp. 1655-1664
-
-
Roodman, G.D.1
-
2
-
-
78049463805
-
Future directions of bone-targeted therapy for metastatic breast cancer
-
Onishi T, Hayashi N, Theriault RL, Hortobagyi GN, Ueno NT. Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol. 2010;7(11):641-651.
-
(2010)
Nat Rev Clin Oncol
, vol.7
, Issue.11
, pp. 641-651
-
-
Onishi, T.1
Hayashi, N.2
Theriault, R.L.3
Hortobagyi, G.N.4
Ueno, N.T.5
-
3
-
-
79961032286
-
Local treatment of metastatic cancer - killing the seed or disturbing the soil?
-
Morgan SC, Parker CC. Local treatment of metastatic cancer - killing the seed or disturbing the soil? Nat Rev Clin Oncol. 2011;8(8):504-506.
-
(2011)
Nat Rev Clin Oncol
, vol.8
, Issue.8
, pp. 504-506
-
-
Morgan, S.C.1
Parker, C.C.2
-
5
-
-
0037009822
-
Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
-
Saad F, Gleason DM, Murray R, T et al. Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458-1468.
-
(2002)
J Natl Cancer Inst
, vol.94
, Issue.19
, pp. 1458-1468
-
-
Saad, F.1
Gleason, D.M.2
Murray, R.3
-
6
-
-
0042914647
-
Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group
-
Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21(16):3150-3157.
-
(2003)
J Clin Oncol
, vol.21
, Issue.16
, pp. 3150-3157
-
-
Rosen, L.S.1
Gordon, D.2
Tchekmedyian, S.3
-
7
-
-
4644340347
-
Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid
-
Lipton A, Colombo-Berra A, Bukowski RM, Rosen L, Zheng M, Urbanowitz G. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res. 2004;10(18 Pt 2):6397S-6403S.
-
(2004)
Clin Cancer Res
, vol.10
, Issue.18 PART 2
-
-
Lipton, A.1
Colombo-Berra, A.2
Bukowski, R.M.3
Rosen, L.4
Zheng, M.5
Urbanowitz, G.6
-
8
-
-
20644449488
-
Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial
-
Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23(15):3314-3321.
-
(2005)
J Clin Oncol
, vol.23
, Issue.15
, pp. 3314-3321
-
-
Kohno, N.1
Aogi, K.2
Minami, H.3
-
9
-
-
4444257291
-
RANKL/RANK/OPG: New therapeutic targets in bone tumours and associated osteolysis
-
Wittrant Y, Théoleyre S, Chipoy C, et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta. 2004;1704(2):49-57.
-
(2004)
Biochim Biophys Acta
, vol.1704
, Issue.2
, pp. 49-57
-
-
Wittrant, Y.1
Théoleyre, S.2
Chipoy, C.3
-
10
-
-
3242781731
-
Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases
-
Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/ RANKL/RANK system for bone and vascular diseases. JAMA. 2004; 292(4):490-495.
-
(2004)
JAMA
, vol.292
, Issue.4
, pp. 490-495
-
-
Hofbauer, L.C.1
Schoppet, M.2
-
11
-
-
33644760436
-
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer
-
Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res. 2006;12(4):1221-1228.
-
(2006)
Clin Cancer Res
, vol.12
, Issue.4
, pp. 1221-1228
-
-
Body, J.J.1
Facon, T.2
Coleman, R.E.3
-
12
-
-
79952761418
-
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma
-
Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125-1132.
-
(2011)
J Clin Oncol
, vol.29
, Issue.9
, pp. 1125-1132
-
-
Henry, D.H.1
Costa, L.2
Goldwasser, F.3
-
13
-
-
84873890067
-
Treatment of advanced renal cell carcinoma
-
In: Kavoussi LR, Novick AC, Partin AW, Peters CA, Wein AJ, editors, 10th ed. New York, NY: Saunders
-
Srinivasan R, Linehan WM. Treatment of advanced renal cell carcinoma. In: Kavoussi LR, Novick AC, Partin AW, Peters CA, Wein AJ, editors. Campbell-Walsh Urology. 10th ed. New York, NY: Saunders; 2011:1475-1491.
-
(2011)
Campbell-Walsh Urology
, pp. 1475-1491
-
-
Srinivasan, R.1
Linehan, W.M.2
-
14
-
-
34247390131
-
European Association of Urology Guideline Group for renal cell carcinoma. Renal cell carcinoma guideline
-
Ljungberg B, Hanbury DC, Kuczyk MA, et al; European Association of Urology Guideline Group for renal cell carcinoma. Renal cell carcinoma guideline. Eur Urol. 2007;51(6):1502-1510.
-
(2007)
Eur Urol
, vol.51
, Issue.6
, pp. 1502-1510
-
-
Ljungberg, B.1
Hanbury, D.C.2
Kuczyk, M.A.3
-
15
-
-
79955524407
-
Treatment outcome and prognostic factors of the patients with renal cell cancer bone metastasis
-
Yuasa T, Urakami S, Yamamoto S, et al. Treatment outcome and prognostic factors of the patients with renal cell cancer bone metastasis. Clin Exp Metastasis. 2011;28(4):405-411.
-
(2011)
Clin Exp Metastasis
, vol.28
, Issue.4
, pp. 405-411
-
-
Yuasa, T.1
Urakami, S.2
Yamamoto, S.3
-
16
-
-
79955522836
-
Management of Bone Metastasis in patients with Renal Cell Carcinoma and Other Malignancies of the Genitourinary Tract
-
In: Kantoff P, Saad F, Smith MR, editors, Philadelphia, PA: FA Davis Co
-
Lipton A. Management of Bone Metastasis in patients with Renal Cell Carcinoma and Other Malignancies of the Genitourinary Tract. In: Kantoff P, Saad F, Smith MR, editors. Management of Skeletal Complications of Prostate Cancer and Other Genitourinary Malignancies. Philadelphia, PA: FA Davis Co; 2004:207-234.
-
(2004)
Management of Skeletal Complications of Prostate Cancer and Other Genitourinary Malignancies
, pp. 207-234
-
-
Lipton, A.1
-
17
-
-
0035433874
-
The skeletal metastatic complications of renal cell carcinoma
-
Zekri J, Ahmed N, Coleman RE, Hancock B W. The skeletal metastatic complications of renal cell carcinoma. Int J Oncol. 2001;19(2): 379-382.
-
(2001)
Int J Oncol
, vol.19
, Issue.2
, pp. 379-382
-
-
Zekri, J.1
Ahmed, N.2
Coleman, R.E.3
Hancock, B.W.4
-
18
-
-
72149129759
-
Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: A cooperative group report of 1463 patients
-
Naito S, Yamamoto N, Takayama T, et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol. 2010;57:317-325.
-
(2010)
Eur Urol
, vol.57
, pp. 317-325
-
-
Naito, S.1
Yamamoto, N.2
Takayama, T.3
-
19
-
-
25844458959
-
Current aspects of the surgical management of organ-confined, metastatic, and recurrent renal cell cancer
-
quiz i-ii
-
Kuczyk MA, Anastasiadis AG, Zimmermann R, Merseburger AS, Corvin S, Stenzi A. Current aspects of the surgical management of organ-confined, metastatic, and recurrent renal cell cancer. BJU Int. 2005;96(5):721-727; quiz i-ii.
-
(2005)
BJU Int
, vol.96
, Issue.5
, pp. 721-727
-
-
Kuczyk, M.A.1
Anastasiadis, A.G.2
Zimmermann, R.3
Merseburger, A.S.4
Corvin, S.5
Stenzi, A.6
-
20
-
-
34249102574
-
Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone
-
Toyoda Y, Shinohara N, Harabayashi T, et al. Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone. Eur Urol. 2007;52(1):163-168.
-
(2007)
Eur Urol
, vol.52
, Issue.1
, pp. 163-168
-
-
Toyoda, Y.1
Shinohara, N.2
Harabayashi, T.3
-
21
-
-
0036138580
-
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
-
Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20(1):289-296.
-
(2002)
J Clin Oncol
, vol.20
, Issue.1
, pp. 289-296
-
-
Motzer, R.J.1
Bacik, J.2
Murphy, B.A.3
Russo, P.4
Mazumdar, M.5
-
22
-
-
84855792427
-
Cancer statistics, 2012
-
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
-
(2012)
CA Cancer J Clin
, vol.62
, Issue.1
, pp. 10-29
-
-
Siegel, R.1
Naishadham, D.2
Jemal, A.3
-
23
-
-
84866248292
-
Management of metastatic and invasive bladder cancer
-
Kavoussi LR, Novick AC, Partin AW, Peters CA, Wein AJ, editors, 10th ed. New York, NY: Saunders
-
Lerner SP, Sternberg CN. Management of metastatic and invasive bladder cancer In: Kavoussi LR, Novick AC, Partin AW, Peters CA, Wein AJ, editors. Campbell-Walsh Urology. 10th ed. New York, NY: Saunders; 2011:2355-2374.
-
(2011)
Campbell-Walsh Urology
, pp. 2355-2374
-
-
Lerner, S.P.1
Sternberg, C.N.2
-
25
-
-
79955629384
-
European Association of Urology (EAU). Treatment of muscle-invasive and metastatic bladder cancer: Update of the EAU guidelines
-
Stenzl A, Cowan NC, De Santis M, et al; European Association of Urology (EAU). Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol. 2011;59(6):1009-1018.
-
(2011)
Eur Urol
, vol.59
, Issue.6
, pp. 1009-1018
-
-
Stenzl, A.1
Cowan, N.C.2
de Santis, M.3
-
26
-
-
0035495693
-
Locally advanced and metastatic bladder cancer
-
Dreicer R. Locally advanced and metastatic bladder cancer. Curr Treat Options Oncol. 2001;2(5):431-436.
-
(2001)
Curr Treat Options Oncol
, vol.2
, Issue.5
, pp. 431-436
-
-
Dreicer, R.1
-
27
-
-
0018956045
-
Metastases from transitional cell carcinoma of urinary bladder
-
Babaian RJ, Johnson DE, Llamas L, Ayala AG. Metastases from transitional cell carcinoma of urinary bladder. Urology. 1980;16(2): 142-144.
-
(1980)
Urology
, vol.16
, Issue.2
, pp. 142-144
-
-
Babaian, R.J.1
Johnson, D.E.2
Llamas, L.3
Ayala, A.G.4
-
28
-
-
0042477610
-
The systemic treatment of advanced and metastatic bladder cancer
-
Hussain SA, James ND. The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol. 2003;4(8):489-497.
-
(2003)
Lancet Oncol
, vol.4
, Issue.8
, pp. 489-497
-
-
Hussain, S.A.1
James, N.D.2
-
29
-
-
0037103074
-
Spanish Oncology Genitourinary Group. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine
-
Bellmunt J, Albanell J, Paz-Ares L, et al; Spanish Oncology Genitourinary Group. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer. 2002;95(4):751-757.
-
(2002)
Cancer
, vol.95
, Issue.4
, pp. 751-757
-
-
Bellmunt, J.1
Albanell, J.2
Paz-Ares, L.3
-
30
-
-
33646892392
-
I/II study of a combined gemcitabine, etoposide, and cisplatin chemotherapy regimen for metastatic urothelial carcinoma
-
Tsukamoto T, Yonese J, Ohkubo Y, Fukui I. Phase I/II study of a combined gemcitabine, etoposide, and cisplatin chemotherapy regimen for metastatic urothelial carcinoma. Cancer. 2006;106(11):2363-2368.
-
(2006)
Cancer
, vol.106
, Issue.11
, pp. 2363-2368
-
-
Tsukamoto, T.1
Yonese, J.2
Ohkubo, Y.3
Phase, F.I.4
-
31
-
-
56449100346
-
Hormonal therapy of prostate cancer
-
In: Kavoussi LR, Novick AC, Partin AW, Peters CA, Wein AJ, editors, 10th ed. New York, NY: Saunders
-
Nelson JB. Hormonal therapy of prostate cancer. In: Kavoussi LR, Novick AC, Partin AW, Peters CA, Wein AJ, editors. Campbell-Walsh Urology. 10th ed. New York, NY: Saunders; 2011:2934-2953.
-
(2011)
Campbell-Walsh Urology
, pp. 2934-2953
-
-
Nelson, J.B.1
-
32
-
-
2642548279
-
Natural history of early, localized prostate cancer
-
Johansson JE, Andrén O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA. 2004;291(22):2713-2719.
-
(2004)
JAMA
, vol.291
, Issue.22
, pp. 2713-2719
-
-
Johansson, J.E.1
Andrén, O.2
Andersson, S.O.3
-
33
-
-
41949104346
-
Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
-
Scher HI, Halabi S, Tannock I, et al; Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148-1159.
-
(2008)
J Clin Oncol
, vol.26
, Issue.7
, pp. 1148-1159
-
-
Scher, H.I.1
Halabi, S.2
Tannock, I.3
-
34
-
-
4744337716
-
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
-
Petrylak D P, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513-1520.
-
(2004)
N Engl J Med
, vol.351
, Issue.15
, pp. 1513-1520
-
-
Petrylak, D.P.1
Tangen, C.M.2
Hussain, M.H.3
-
35
-
-
4744366279
-
TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
-
Tannock IF, de Wit R, Berry WR, et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-1512.
-
(2004)
N Engl J Med
, vol.351
, Issue.15
, pp. 1502-1512
-
-
Tannock, I.F.1
de Wit, R.2
Berry, W.R.3
-
36
-
-
35348839555
-
Zoledronic acid - a multiplicity of anti-cancer action
-
Yuasa T, Kimura S, Ashihara E, Habuchi T, Maekawa T. Zoledronic acid - a multiplicity of anti-cancer action. Curr Med Chem. 2007;14(20): 2126-2135.
-
(2007)
Curr Med Chem
, vol.14
, Issue.20
, pp. 2126-2135
-
-
Yuasa, T.1
Kimura, S.2
Ashihara, E.3
Habuchi, T.4
Maekawa, T.5
-
37
-
-
0842278680
-
Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anti- cancer drugs in leukemic cell lines
-
Kimura S, Kuroda J, Segawa H, et al. Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anti- cancer drugs in leukemic cell lines. Int J Hematol. 2004;79(1):37-43.
-
(2004)
Int J Hematol
, vol.79
, Issue.1
, pp. 37-43
-
-
Kimura, S.1
Kuroda, J.2
Segawa, H.3
-
38
-
-
10444274954
-
Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines
-
Matsumoto S, Kimura S, Segawa S, et al. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer. 2005;47: 31-39.
-
(2005)
Lung Cancer
, vol.47
, pp. 31-39
-
-
Matsumoto, S.1
Kimura, S.2
Segawa, S.3
-
39
-
-
33646107396
-
Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro
-
Neville-Webbe HL, Evans CA, Coleman RE, Holen I. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol. 2006;27(2):92-103.
-
(2006)
Tumour Biol
, vol.27
, Issue.2
, pp. 92-103
-
-
Neville-Webbe, H.L.1
Evans, C.A.2
Coleman, R.E.3
Holen, I.4
-
40
-
-
0035917560
-
Rostami-H A, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel
-
Jagdev S P, Coleman RE, Shipman CM, Rostami-H A, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001;84(8): 1126-1134.
-
(2001)
Br J Cancer
, vol.84
, Issue.8
, pp. 1126-1134
-
-
Jagdev, S.P.1
Coleman, R.E.2
Shipman, C.M.3
-
41
-
-
5344237455
-
Osteoporosis and obesity in men receiving hormone therapy for prostate cancer
-
Smith MR. Osteoporosis and obesity in men receiving hormone therapy for prostate cancer. J Urol. 2004;172(5 Pt 2):S52-S56.
-
(2004)
J Urol
, vol.172
, Issue.5 PART 2
-
-
Smith, M.R.1
-
42
-
-
58249123472
-
Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy
-
Wang W, Yuasa T, Tsuchiya N, et al. Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy. Endocr Relat Cancer. 2008;15(4):943-952.
-
(2008)
Endocr Relat Cancer
, vol.15
, Issue.4
, pp. 943-952
-
-
Wang, W.1
Yuasa, T.2
Tsuchiya, N.3
-
43
-
-
77951666249
-
Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients
-
Yuasa T, Maita S, Tsuchiya N, et al. Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. Urolog y. 2010;75(5):1131-1137.
-
(2010)
Urolog Y
, vol.75
, Issue.5
, pp. 1131-1137
-
-
Yuasa, T.1
Maita, S.2
Tsuchiya, N.3
-
44
-
-
84928580276
-
Hodges VC. Studies on prostate cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
-
Huggins C, Hodges VC. Studies on prostate cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293-297.
-
(1941)
Cancer Res
, vol.1
, pp. 293-297
-
-
Huggins, C.1
-
45
-
-
0042463650
-
National practice patterns and time trends in androgen ablation for localized prostate cancer
-
Cooperberg MR, Grossfeld GD, Lubeck D P, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst. 2003;95(13):981-989.
-
(2003)
J Natl Cancer Inst
, vol.95
, Issue.13
, pp. 981-989
-
-
Cooperberg, M.R.1
Grossfeld, G.D.2
Lubeck, D.P.3
Carroll, P.R.4
-
46
-
-
22144484150
-
Androgen deprivation therapy for prostate cancer
-
Sharif N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238-244.
-
(2005)
JAMA
, vol.294
, Issue.2
, pp. 238-244
-
-
Sharif, N.1
Gulley, J.L.2
Dahut, W.L.3
-
47
-
-
0037299782
-
Side effects of androgen deprivation therapy: Monitoring and minimizing toxicity
-
Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology. 2003;61(2 Suppl 1):32-38.
-
(2003)
Urology
, vol.61
, Issue.2 SUPPL. 1
, pp. 32-38
-
-
Higano, C.S.1
-
48
-
-
11844252588
-
Risk of fracture after androgen deprivation for prostate cancer
-
Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2): 154-164.
-
(2005)
N Engl J Med
, vol.352
, Issue.2
, pp. 154-164
-
-
Shahinian, V.B.1
Kuo, Y.F.2
Freeman, J.L.3
Goodwin, J.S.4
-
49
-
-
28744454444
-
Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer
-
Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005;90(12): 6410-6417.
-
(2005)
J Clin Endocrinol Metab
, vol.90
, Issue.12
, pp. 6410-6417
-
-
Greenspan, S.L.1
Coates, P.2
Sereika, S.M.3
Nelson, J.B.4
Trump, D.L.5
Resnick, N.M.6
-
50
-
-
30344468795
-
Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy
-
Bruder JM, Ma JZ, Basler J W, Welch MD. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy. Urology. 2006;67(1):152-155.
-
(2006)
Urology
, vol.67
, Issue.1
, pp. 152-155
-
-
Bruder, J.M.1
Ma, J.Z.2
Basler, J.W.3
Welch, M.D.4
-
51
-
-
33947222498
-
Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer
-
Morote J, Morin J P, Orsola A, et al. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology. 2007;69(3):500-504.
-
(2007)
Urology
, vol.69
, Issue.3
, pp. 500-504
-
-
Morote, J.1
Morin, J.P.2
Orsola, A.3
-
52
-
-
33645987269
-
Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression
-
Morote J, Orsola A, Abascal JM, et al. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. J Urol. 2007;175(5):1679-1683.
-
(2007)
J Urol
, vol.175
, Issue.5
, pp. 1679-1683
-
-
Morote, J.1
Orsola, A.2
Abascal, J.M.3
-
53
-
-
0036296523
-
Clinical predictors of androgen-independent prostate cancer and survival in the prostate- specifc antigen era
-
Oefelein MG, Ricchiuti VS, Conrad P W, et al. Clinical predictors of androgen-independent prostate cancer and survival in the prostate- specifc antigen era. Urology. 2002;60(1):120-124.
-
(2002)
Urology
, vol.60
, Issue.1
, pp. 120-124
-
-
Oefelein, M.G.1
Ricchiuti, V.S.2
Conrad, P.W.3
-
54
-
-
67650924224
-
Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas
-
Mikami S, Katsube K, Oya M, et al. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas. J Pathol. 2009;218(4):530-539.
-
(2009)
J Pathol
, vol.218
, Issue.4
, pp. 530-539
-
-
Mikami, S.1
Katsube, K.2
Oya, M.3
-
55
-
-
33745821237
-
Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation
-
Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer. 2006;107(2):289-298.
-
(2006)
Cancer
, vol.107
, Issue.2
, pp. 289-298
-
-
Chen, G.1
Sircar, K.2
Aprikian, A.3
Potti, A.4
Goltzman, D.5
Rabbani, S.A.6
-
56
-
-
51249088776
-
A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer
-
Narita N, Yuasa T, Tsuchiya N, et al. A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer. BMC Cancer. 2008;8:224.
-
(2008)
BMC Cancer
, vol.8
, pp. 224
-
-
Narita, N.1
Yuasa, T.2
Tsuchiya, N.3
-
57
-
-
0036148405
-
Development of bisphosphonates
-
Fleisch H. Development of bisphosphonates. Breast Cancer Res. 2002; 4(1):30-34.
-
(2002)
Breast Cancer Res
, vol.4
, Issue.1
, pp. 30-34
-
-
Fleisch, H.1
-
58
-
-
77955457605
-
A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer
-
Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I, Nazmy M. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol. 2010;15(4): 382-389.
-
(2010)
Int J Clin Oncol
, vol.15
, Issue.4
, pp. 382-389
-
-
Zaghloul, M.S.1
Boutrus, R.2
El-Hossieny, H.3
Kader, Y.A.4
El-Attar, I.5
Nazmy, M.6
-
59
-
-
12244295754
-
A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon αβ-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo
-
Yuasa T, Nogawa M, Kimura S, et al. A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon αβ-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo. Clin Cancer Res. 2005;11(2 Pt 1):853-859.
-
(2005)
Clin Cancer Res
, vol.11
, Issue.2 PART 1
, pp. 853-859
-
-
Yuasa, T.1
Nogawa, M.2
Kimura, S.3
-
60
-
-
33751034291
-
A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo
-
Sato K, Yuasa T, Nogawa M, et al. A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. Br J Cancer. 2006;95(10):1354-1361.
-
(2006)
Br J Cancer
, vol.95
, Issue.10
, pp. 1354-1361
-
-
Sato, K.1
Yuasa, T.2
Nogawa, M.3
-
61
-
-
82255162986
-
Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function
-
Maita S, Yuasa T, Tsuchiya N, et al. Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function. Int J Cancer. 2012;130(3):677-684.
-
(2012)
Int J Cancer
, vol.130
, Issue.3
, pp. 677-684
-
-
Maita, S.1
Yuasa, T.2
Tsuchiya, N.3
-
62
-
-
33645453481
-
Regulation of cancer cell migration and bone metastasis by RANKL
-
Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006;440(7084): 692-696.
-
(2006)
Nature
, vol.440
, Issue.7084
, pp. 692-696
-
-
Jones, D.H.1
Nakashima, T.2
Sanchez, O.H.3
-
63
-
-
78149284767
-
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis
-
Gonzalez-Suarez E, Jacob A P, Jones J, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature. 2010;468(7320):103-107.
-
(2010)
Nature
, vol.468
, Issue.7320
, pp. 103-107
-
-
Gonzalez-Suarez, E.1
Jacob, A.P.2
Jones, J.3
-
64
-
-
51049121618
-
RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis
-
Miller RE, Roudier M, Jones J, Armstrong A, Canon J, Dougall WC. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther. 2008;7(7):2160-2169.
-
(2008)
Mol Cancer Ther
, vol.7
, Issue.7
, pp. 2160-2169
-
-
Miller, R.E.1
Roudier, M.2
Jones, J.3
Armstrong, A.4
Canon, J.5
Dougall, W.C.6
-
65
-
-
69049105440
-
Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen- deprivation therapy for prostate cancer
-
Smith MR, Egerdie B, Hernández Toriz N, et al; Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen- deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8): 745-755.
-
(2009)
N Engl J Med
, vol.361
, Issue.8
, pp. 745-755
-
-
Smith, M.R.1
Egerdie, B.2
Hernándeztoriz, N.3
-
66
-
-
79952360832
-
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study
-
Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377(9768):813-822.
-
(2011)
Lancet
, vol.377
, Issue.9768
, pp. 813-822
-
-
Fizazi, K.1
Carducci, M.2
Smith, M.3
-
67
-
-
84855516339
-
Denosumab and bone-metastasis- free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial
-
Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis- free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012;379(9810): 39-46.
-
(2012)
Lancet
, vol.379
, Issue.9810
, pp. 39-46
-
-
Smith, M.R.1
Saad, F.2
Coleman, R.3
|